Skip to main content
Clinical Trials/NCT04456725
NCT04456725
Unknown
Not Applicable

Intensive Management of At-risk Patients: a Randomized Controlled Trial

CareMore Health, San Bernardino0 sites600 target enrollmentJuly 1, 2020
ConditionsChronic Disease

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Disease
Sponsor
CareMore Health, San Bernardino
Enrollment
600
Primary Endpoint
inpatient bed days
Last Updated
5 years ago

Overview

Brief Summary

The purpose of this study is to assess if intensive management of at-risk participants, utilizing longitudinal patient tracking, proactive outreach, multidisciplinary action planning and careful outcomes monitoring, will lead to better patient outcomes than usual care.

Detailed Description

At-risk participants will be randomized 1:1 to either usual care or intensive management utilizing longitudinal patient tracking, proactive outreach, multidisciplinary action planning and careful outcomes monitoring for 6 months. Participants in the intervention group will be assigned to a partnership of one nurse practitioner and one medical assistant who will manage them with the support of the study team. Staff will focus on contacting all patients within one week of any emergency department visit or hospital discharge, contacting all highest-risk participants weekly and all participants monthly, and completing high-priority tasks for participant care within one week. The primary outcomes of this quality improvement study are inpatient bed days and number of inpatient admissions.

Registry
clinicaltrials.gov
Start Date
July 1, 2020
End Date
December 31, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
CareMore Health, San Bernardino
Responsible Party
Principal Investigator
Principal Investigator

Paul Bixenstine

Primary Care Physician

CareMore Health, San Bernardino

Eligibility Criteria

Inclusion Criteria

  • At-risk patients, meaning Gold, Silver, or Bronze tier, as identified by our member 360 platform:
  • Gold tier - 6+ emergency department (ED) visits last year, annual spend \>$100,000, 8 or more hierarchical condition category (HCC) diagnoses, readmission \<30 days prior, or ambulatory care-sensitive condition (ACSC) hospitalization \<30 days prior
  • Silver tier - 4+ ED visits last year, annual spend \>$75,000, 6 or more HCC diagnoses, readmission \<90 days prior, substance abuse HCC diagnosis, behavioral health admit \<90 days, 15+ chronic medications prescribed in the last 90 days (and not qualifying for Gold tier)
  • Bronze tier - 3+ ED visits last year, annual spend \>$50,000, 5 or more HCC diagnoses, 3+ hospitalizations last year, end-stage liver disease, end-stage renal disease, Medicare and Medicaid dual-enrolled, disease-management program patients with ACSC admission or ED visit in the last year, 10+ chronic medications in the last 90 days, 6+ health risk-assessment score, 12+ Edmonton Frail Scale score (and not qualifying for Gold or Silver tiers)

Exclusion Criteria

  • enrolled in hospice
  • enrolled in Institutional Special Needs Plan
  • primary patient of study investigator

Outcomes

Primary Outcomes

inpatient bed days

Time Frame: 6 months

number of total participants' days of care in an inpatient setting

inpatient admissions

Time Frame: 6 months

total number of participants' inpatient admissions

Secondary Outcomes

  • cost(6 months)
  • average percent of participants contacted monthly(1 month)
  • inpatient plus SNF bed days(6 months)
  • average change in percent of high-priority HEDIS gaps(6 months)
  • ED visits(6 months)
  • 30-day readmissions(30 days)
  • 180-day readmissions(180 days)
  • ACSC admits(6 months)
  • delta MLR(6 months)
  • average change in staff satisfaction score(6 months)
  • average percent post-acute contact within 1 week(1 week)
  • average percent of high-priority tasks completed within 1 week(1 week)
  • average percent of Gold patients contacted weekly(1 week)
  • average change in participant satisfaction score(6 months)

Similar Trials